Modular assembly of cell-targeting devices based on an uncommon G-quadruplex aptamer

Molecular Therapy Nucleic Acids

Volumn 4, Issue , 2015, Pages e251-

  Opazo, Felipe ^a   Eiden, Laura ^b   Hansen, Line ^c   Rohrbach, Falk ^b   Wengel, Jesper ^d   Kjems, Jørgen ^c   Mayer, Günter ^b  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c AARHUS UNIVERSITY   (Denmark)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Aptamers; bi paratopic; Burkitts lymphoma; G cuadruplex; RAMOS

Indexed keywords

APTAMER; CLATHRIN; GUANINE QUADRUPLEX; QUANTUM DOT;

ARTICLE; BURKITT LYMPHOMA; BURKITT LYMPHOMA CELL LINE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DNA LIBRARY; ENDOCYTOSIS; HUMAN; HUMAN CELL; INTERNALIZATION; NUCLEOTIDE MOTIF; PINOCYTOSIS; POINT MUTATION; PRIORITY JOURNAL; TARGET CELL;

EID: 84940825848     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2015.25     Document Type: Article

References (47)

1. Bagalkot, V, Farokhzad, OC, Langer, R and Jon, S (2006). An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew Chem Int Ed Engl 45: 8149-8152.
2. Esposito, CL, Cerchia, L, Catuogno, S, De Vita, G, Dassie, JP, Santamaria, G et al. (2014). Multifunctional aptamer-miRNA conjugates for targeted cancer therapy. Mol Ther 22: 1151-1163.
3. Chu, TC, Twu, KY, Ellington, AD and Levy, M (2006). Aptamer mediated siRNA delivery. Nucleic Acids Res 34: e73.
4. Pofahl, M, Wengel, J and Mayer, G (2014). Multifunctional nucleic acids for tumor cell treatment. Nucleic Acid Ther 24: 171-177.
5. Catuogno, S, Rienzo, A, Di Vito, A, Esposito, CL and de Franciscis, V (2015). Selective delivery of therapeutic single strand antimiRs by aptamer-based conjugates. J Control Release 210: 147-159.
6. Xu, X, Ho, W, Zhang, X, Bertrand, N and Farokhzad, O (2015). Cancer nanomedicine: from targeted delivery to combination therapy. Trends Mol Med 21: 223-232.
7. Zhu, H, Li, J, Zhang, XB, Ye, M and Tan, W (2015). Nucleic acid aptamer-mediated drug delivery for targeted cancer therapy. ChemMedChem 10: 39-45.
8. Zhou, J and Rossi, JJ (2014). Cell-type-specific, Aptamer-functionalized Agents for Targeted Disease Therapy. Mol Ther Nucleic Acids 3: e169.
9. Cibiel, A, Quang, NN, Gombert, K, Thézé, B, Garofalakis, A and Ducongé, F (2014). From ugly duckling to swan: unexpected identification from cell-SELEX of an anti-Annexin A2 aptamer targeting tumors. PLoS One 9: e87002.
10. Lupold, SE, Hicke, BJ, Lin, Y and Coffey, DS (2002). Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostatespecific membrane antigen. Cancer Res 62: 4029-4033.
11. Farokhzad, OC, Cheng, J, Teply, BA, Sherifi, I, Jon, S, Kantoff, PW et al. (2006). Targeted nanoparticle-Aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA 103: 6315-6320.
12. McNamara, JO 2nd, Andrechek, ER, Wang, Y, Viles, KD, Rempel, RE, Gilboa, E et al. (2006). Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 24: 1005-1015.
13. Yan, AC and Levy, M (2009). Aptamers and aptamer targeted delivery. RNA Biol 6: 316-320.
14. Kruspe, S and Hahn, U (2014). An aptamer intrinsically comprising 5-fluoro-2'-deoxyuridine for targeted chemotherapy. Angew Chem Int Ed Engl 53: 10541-10544.
15. Takahashi, M, Burnett, JC and Rossi, JJ (2015). Aptamer-siRNA chimeras for HIV. Adv Exp Med Biol 848: 211-234.
16. Wengerter, BC, Katakowski, JA, Rosenberg, JM, Park, CG, Almo, SC, Palliser, D et al. (2014). Aptamer-targeted antigen delivery. Mol Ther 22: 1375-1387.
17. Dassie, JP, Liu, XY, Thomas, GS, Whitaker, RM, Thiel, KW, Stockdale, KR et al. (2009). Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol 27: 839-849.
18. Xiao, Z and Farokhzad, OC (2012). Aptamer-functionalized nanoparticles for medical applications: challenges and opportunities. ACS Nano 6: 3670-3676.
19. Mayer, G, Ahmed, MS, Dolf, A, Endl, E, Knolle, PA and Famulok, M (2010). Fluorescenceactivated cell sorting for aptamer SELEX with cell mixtures. Nat Protoc 5: 1993-2004.
20. Raddatz, MS, Dolf, A, Endl, E, Knolle, P, Famulok, M and Mayer, G (2008). Enrichment of cell-targeting and population-specific aptamers by fluorescence-Activated cell sorting. Angew Chem Int Ed Engl 47: 5190-5193.
21. Magbanua, E, Zivkovic, T, Hansen, B, Beschorner, N, Meyer, C, Lorenzen, I et al. (2013). d(GGGT) 4 and r(GGGU) 4 are both HIV-1 inhibitors and interleukin-6 receptor aptamers. RNA Biol 10: 216-227.
22. Meyer, C, Eydeler, K, Magbanua, E, Zivkovic, T, Piganeau, N, Lorenzen, I et al. (2012). Interleukin-6 receptor specific RNA aptamers for cargo delivery into target cells. RNA Biol 9: 67-80.
23. Mayer, G, Kröck, L, Mikat, V, Engeser, M and Heckel, A (2005). Light-induced formation of G-quadruplex DNA secondary structures. Chembiochem 6: 1966-1970.
24. Mukundan, VT, Do, NQ and Phan, AT (2011). HIV-1 integrase inhibitor T30177 forms a stacked dimeric G-quadruplex structure containing bulges. Nucleic Acids Res 39: 8984-8991.
25. Mukundan, VT and Phan, AT (2013). Bulges in G-quadruplexes: broadening the definition of G-quadruplex-forming sequences. J Am Chem Soc 135: 5017-5028.
26. Campbell, MA and Wengel, J (2011). Locked vs. unlocked nucleic acids (LNA vs. UNA): contrasting structures work towards common therapeutic goals. Chem Soc Rev 40: 5680-5689.
27. Wahlestedt, C, Salmi, P, Good, L, Kela, J, Johnsson, T, Hökfelt, T et al. (2000). Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc Natl Acad Sci USA 97: 5633-5638.
28. Bonifacio, L, Church, FC and Jarstfer, MB (2008). Effect of locked-nucleic acid on a biologically active g-quadruplex. A structure-Activity relationship of the thrombin aptamer. Int J Mol Sci 9: 422-433.
29. Rohrbach, F, Fatthalla, MI, Kupper, T, Pötzsch, B, Müller, J, Petersen, M et al. (2012). Chemical maturation of a bivalent aptamer by single domain variation. Chembiochem 13: 631-634.
30. Bing, T, Yang, X, Mei, H, Cao, Z and Shangguan, D (2010). Conservative secondary structure motif of streptavidin-binding aptamers generated by different laboratories. Bioorg Med Chem 18: 1798-1805.
31. Codelli, JA, Baskin, JM, Agard, NJ and Bertozzi, CR (2008). Second-generation difluorinated cyclooctynes for copper-free click chemistry. J Am Chem Soc 130: 11486-11493.
32. Navaroli, DM, Bellvé, KD, Standley, C, Lifshitz, LM, Cardia, J, Lambright, D et al. (2012). Rabenosyn-5 defines the fate of the transferrin receptor following clathrin-mediated endocytosis. Proc Natl Acad Sci USA 109: E471-E480.
33. Pustylnikov, S, Sagar, D, Jain, P and Khan, ZK (2014). Targeting the C-type lectinsmediated host-pathogen interactions with dextran. J Pharm Pharm Sci 17: 371-392.
34. Kirchhausen, T, Macia, E and Pelish, HE (2008). Use of dynasore, the small molecule inhibitor of dynamin, in the regulation of endocytosis. Methods Enzymol 438: 77-93.
35. Wilner, SE, Wengerter, B, Maier, K, de Lourdes Borba Magalhães, M, Del Amo, DS, Pai, S et al. (2012). An RNA alternative to human transferrin: a new tool for targeting human cells. Mol Ther Nucleic Acids 1: e21.
36. Reyes-Reyes, EM, Teng, Y and Bates, PJ (2010). A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism. Cancer Res 70: 8617-8629.
37. Varkouhi, AK, Scholte, M, Storm, G and Haisma, HJ (2011). Endosomal escape pathways for delivery of biologicals. J Control Release 151: 220-228.
38. Nguyen, J and Szoka, FC (2012). Nucleic acid delivery: the missing pieces of the puzzle? Acc Chem Res 45: 1153-1162.
39. Dollins, CM, Nair, S, Boczkowski, D, Lee, J, Layzer, JM, Gilboa, E et al. (2008). Assembling OX40 aptamers on a molecular scaffold to create a receptor-Activating aptamer. Chem Biol 15: 675-682.
40. McNamara, JO, Kolonias, D, Pastor, F, Mittler, RS, Chen, L, Giangrande, PH et al. (2008). Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. J Clin Invest 118: 376-386.
41. Zhou, J, Soontornworajit, B, Martin, J, Sullenger, BA, Gilboa, E and Wang, Y (2009). A hybrid DNA aptamer-dendrimer nanomaterial for targeted cell labeling. Macromol Biosci 9: 831-835.
42. Schmidt, KS, Borkowski, S, Kurreck, J, Stephens, AW, Bald, R, Hecht, M et al. (2004). Application of locked nucleic acids to improve aptamer in vivo stability and targeting function. Nucleic Acids Res 32: 5757-5765.
43. Mallikaratchy, P, Tang, Z, Kwame, S, Meng, L, Shangguan, D and Tan, W (2007). Aptamer directly evolved from live cells recognizes membrane bound immunoglobin heavy mu chain in Burkitt's lymphoma cells. Mol Cell Proteomics 6: 2230-2238.
44. Vinkenborg, JL, Mayer, G and Famulok, M (2012). Aptamer-based affinity labeling of proteins. Angew Chem Int Ed Engl 51: 9176-9180.
45. Müller, J, Isermann, B, Dücker, C, Salehi, M, Meyer, M, Friedrich, M et al. (2009). An exosite-specific ssDNA aptamer inhibits the anticoagulant functions of activated protein C and enhances inhibition by protein C inhibitor. Chem Biol 16: 442-451.
46. Mayer, G, Wulffen, B, Huber, C, Brockmann, J, Flicke, B, Neumann, L et al. (2008). An RNA molecule that specifically inhibits G-protein-coupled receptor kinase 2 in vitro. RNA 14: 524-534.
47. Mayer, G and Höver, T (2009). In vitro selection of ssDNA aptamers using biotinylated target proteins. Methods Mol Biol 535: 19-32.